GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/IBD/A Normal UCEIS Is Zero, not Three: Gastroenterology | March 26
58

A Normal UCEIS Is Zero, not Three: Gastroenterology | March 26

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated March 1, 2026

Introduction

The Ulcerative Colitis Endoscopic Index of Severity (UCEIS) was developed to standardise the endoscopic assessment of ulcerative colitis activity. It evaluates vascular pattern, bleeding, and erosions/ulcers, generating a score reflecting disease severity. Although initially described with a range of 3–11, subsequent validation rebased the scoring system to 0–8, making a completely normal colonoscopy score 0. Despite this revision, confusion about the correct scoring persists in clinical practice and literature.

Summary

This commentary highlights ongoing misconceptions regarding the UCEIS scoring system and emphasises the importance of adopting the validated 0–8 scale. The rebasing from 3–11 to 0–8 improved clinical interpretation, so a normal colonoscopy now scores 0 rather than 3. However, surveys among inflammatory bowel disease specialists revealed that over one-third still believe a normal colonoscopy corresponds to a score of 3. Literature review also identified multiple publications, guideline documents, and online calculators continuing to reference the outdated scale. This inconsistency may influence research and clinical decision-making, as UCEIS is increasingly used to guide treatment escalation and predict outcomes, including response to intravenous steroids in acute severe ulcerative colitis. The authors call for universal adoption of the validated scoring system and improved educational resources, including standardised image examples for each descriptor. Establishing a common understanding of UCEIS is essential for reliable communication, accurate disease assessment, and consistency across clinical care and research in ulcerative colitis.

Related Q&A

59

VECTORS Trial - BMJ Open Gastro Feb. 26

The VECTORS trial, a landmark phase 4 randomized controlled trial (RCT), was recently published in BMJ Open Gastroenterology on February 26. This trial represents a significant step forward...

60

Caffeine and IBD - JGH Feb 26

This is the first comprehensive meta-analysis examining the relationship between caffeine intake and inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), synthesising data from...

61

Subcutaneous Guselkumab for Crohn’s: Interpreting GRAVITI Carefully- Gastroenterology Feb.26

Introduction Fully subcutaneous biologic regimens are attractive in Crohn’s disease because they can reduce infusion burden and improve convenience. The GRAVITI trial evaluated a fully subcutaneous induction and...

62

Inpatient IBD Care: Practical Guidance From the AGA- Gastroenterology Feb.26

Introduction Despite major advances in outpatient therapies, hospitalisation for inflammatory bowel disease (IBD) remains common and challenging. Outcomes vary widely, with persistent problems such as: hospital-acquired complications, delays...

63

From Treatment to Prevention in IBD - Gastroenterology Feb.26

Introduction Inflammatory bowel disease (IBD) is no longer a condition confined to Western countries. With globalisation, urbanisation, and changing environmental exposures, IBD incidence is rising worldwide, while prevalence...

64

Nutrition management puzzle in IBD- Front. Med. 2026

Nutritional Management in IBD: Current Insights Importance of Nutrition in IBD: Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is influenced by genetic,...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer